We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
Hot Features
Premium
TIDMSHP
Shire to announce third quarter 2018 results
Dublin, Ireland -- October 18, 2018 -- Shire plc (LSE: SHP, NASDAQ:
SHPG), will announce third quarter 2018 earnings on Thursday November 1,
2018.
Results press release will 12:00 GMT / 08:00 EDT
be issued at:
Investor conference call 14:00 GMT / 10:00 EDT
time:
Live conference call for investors:
Flemming Ornskov, MD, M.P.H., Chief Executive Officer and Thomas
Dittrich, Chief Financial Officer will host the investor and analyst
conference call at 10:00 am EDT / 14:00 GMT.
The details of the conference call are as follows:
UK dial in: 0800 358 9473 or +44 333 300
0804
US dial in: 1 855 857 0686 or 1 631 913
1422
International Access Click here:
Numbers: http://events.arkadin.com/ev/docs/NE_W2_TF_Events_International_A
ccess_List.pdf
Password/Conf ID: 28705371 #
Live Webcast: Click here
http://investors.shire.com/presentations-and-reports/quarterly-re
sults-and-presentations
Replay:
A replay of the presentation will be made available, subject to approval
by the UK Takeover Panel, for two weeks by phone and for three months by
webcast. Replay information made available will be contained on the
Investor Relations section of Shire's website at
http://investors.shire.com/.
For further information please contact:
Investor Relations
Christoph Brackmann christoph.brackmann@shire.com +41 41 288 4129
Sun Kim sun.kim@shire.com +1 617 588 8175
Scott Burrows scott.burrows@shire.com +41 41 288 4195
Media
Katie Joyce kjoyce@shire.com +1 781 482 2779
NOTES TO EDITORS
About Shire
Shire is the global biotechnology leader serving patients with rare
diseases and specialized conditions. We seek to push boundaries through
discovering and delivering new possibilities for patient communities who
often have few or no other champions. Relentlessly on the edge of what's
next, we are serial innovators with a diverse pipeline offering fresh
thinking and new hope. Serving patients and partnering with healthcare
communities in over 100 countries, we strive to be part of the entire
patient journey to enable earlier diagnosis, raise standards of care,
accelerate access to treatment, and support patients. Our diverse
portfolio of therapeutic areas includes Immunology, Hematology, Genetic
Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
Championing patients is our call to action - it brings the opportunity -
and responsibility - to change people's lives.
www.shire.com
(END) Dow Jones Newswires
October 18, 2018 07:15 ET (11:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
